Gan & Lee Pharmaceuticals (603087.SH) announced that it has recently received drug registration approvals for its Insulin Glargine Injection and Insulin Glargine Injection Pre-filled Pen from the Ethiopian Food and Drug Administration (approval numbers: 11865/13208/NMR/2025, 11864/13210/NMR/2025). Insulin Glargine is a long-acting basal insulin administered via subcutaneous injection once daily, providing a blood sugar-lowering effect that lasts for 24 hours. It is characterized by its prolonged duration of action, stable and peak-free blood concentration levels, and consistent blood glucose control.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments